<DOC>
	<DOCNO>NCT02095210</DOCNO>
	<brief_summary>This open-labeled , exploratory , single center study . Patients big primary breast cancer ( ≥ 3 cm ) metastatic first line , routinely HER2-expression determine biopsy . Patients HER2-positive tumor recruit study . A [ 18F ] FDG PET/ceCT scan perform measurement uptake tumour diagnosis possible metastasis . Each subject receive single injection investigational product [ 68Ga ] ABY-025 , follow measurement uptake tumour metastasis normal organ . The investigation repeat HER2 direct therapy .</brief_summary>
	<brief_title>HER2 PET Imaging Breast Cancer Patients Using 68GAABY-025</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Subject &gt; 18 year age 2 . Histologically cytologically confirm diagnosis breast adenocarcinoma ≥ 3 cm determine ultrasound , locally advanced breast cancer ( LABC : T34NxMx TxN23Mx ) 3 . HER2positiv breast cancer first recurrence 4 . HER2positiv breast cancer primary metastatic 5 . HER2 status determine biopsy material primary tumour find HER2positive , define DAKO HercepTest™ score 3+ else 2+ FISH positive 6 . [ 18F ] FDG PET/ceCT perform within 7 day administration IMP 7 . ECOG performance status = &lt; 2 8 . Hematological , liver renal function test result within follow limit : White blood cell count : &gt; 2.0 x 10^9/L Haemoglobin : &gt; 5.0 mmol/L Platelets : &gt; 50.0 x 10^9/L ALT , ALP : = &lt; 3 time Upper Limit Normal Bilirubin = &lt; 2.0 time Upper Limit Normal Serum creatinine : Within Normal Limits 9 . A negative pregnancy test ( serum betaHCG ) screen subject childbearing potential 10 . Subject capable undergo diagnostic investigation perform study 11 . Informed consent 1 . Known hypersensitivity Dotarem® 2 . Active know autoimmune disease history autoimmune disease 3 . Active serious infection accord investigator evaluation 4 . Known HIV positive chronically active hepatitis B C 5 . Administration investigational medicinal product within 30 day screen 6 . Pregnant breastfeed 7 . Women capable childbearing use sufficient nonhormonal method birth control 8 . Other primary malignancy ( include primary brain tumor ) within last 5 year inclusion , exception sufficiently treat situ carcinoma cervix , squamous carcinoma skin sufficiently control limited basal cell carcinoma skin 9 . Signs disease , metabolic psychological dysfunction , finding physical examination laboratory finding , give reasonable suspicion disease condition would contraindicate use IMP , could influence patient 's compliance study routines involves increase risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>PET scan</keyword>
	<keyword>HER2</keyword>
	<keyword>breast cancer</keyword>
</DOC>